Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Wilms Tumor 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Sarcoma 6Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Histiocytosis, Langerhans-Cell 6Glioma 6Ependymoma 6Central Nervous System Neoplasms 5Sarcoma, Ewing 4Multiple Myeloma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lung Neoplasms 3Colorectal Neoplasms 3Rectal Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Nasopharyngeal Carcinoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Endometrial Neoplasms 2Desmoid Tumors 2Carcinoma, Non-Small-Cell Lung 2

Interventions

pembrolizumab 44Gemcitabine 23enfortumab vedotin 21Nivolumab 20Cisplatin 17avelumab 16Magnetic Resonance Spectroscopy 15Carboplatin 14atezolizumab 13Specimen Handling 12Docetaxel 11sacituzumab govitecan 9Paclitaxel 8Ipilimumab 8durvalumab 6Mitomycin 5Fluorodeoxyglucose F18 5cabozantinib 4Taxes 4toripalimab 3pemigatinib 3erdafitinib 3X-Rays 3Radiosurgery 3Platinum 3Pemetrexed 3Immunoglobulin G 3CTLA-4 Antigen 3Biopsy 3ALT-803 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Phantoms, Imaging × 1 year × Clear all
NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

University of California, San Francisco

Phase 1 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡